These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 8019514)

  • 1. Silymarin and its components are inhibitors of beta-glucuronidase.
    Kim DH; Jin YH; Park JB; Kobashi K
    Biol Pharm Bull; 1994 Mar; 17(3):443-5. PubMed ID: 8019514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intestinal bacterial beta-glucuronidase activity of patients with colon cancer.
    Kim DH; Jin YH
    Arch Pharm Res; 2001 Dec; 24(6):564-7. PubMed ID: 11794536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatoprotective effect of lactic acid bacteria, inhibitors of beta-glucuronidase production against intestinal microflora.
    Han SY; Huh CS; Ahn YT; Lim KS; Baek YJ; Kim DH
    Arch Pharm Res; 2005 Mar; 28(3):325-9. PubMed ID: 15832821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of beta-glucosidase and beta-glucuronidase of alkalotolerant intestinal bacteria.
    Kim DH; Kang HJ; Park SH; Kobashi K
    Biol Pharm Bull; 1994 Mar; 17(3):423-6. PubMed ID: 8019510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatoprotective activity of reduohanxiao-tang (yuldahanso-tang) is related to the inhibition of beta-glucuronidase.
    Bae HS; Kim YS; Cho KH; Lee KS; Kim JJ; Lee HU; Kim DH
    Am J Chin Med; 2003; 31(1):111-7. PubMed ID: 12723760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beta-glucuronidase inhibitory activity and hepatoprotective effect of 18 beta-glycyrrhetinic acid from the rhizomes of Glycyrrhiza uralensis.
    Shim SB; Kim NJ; Kim DH
    Planta Med; 2000 Feb; 66(1):40-3. PubMed ID: 10705732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatoprotective mechanism of silymarin: no evidence for involvement of cytochrome P450 2E1.
    Miguez MP; Anundi I; Sainz-Pardo LA; Lindros KO
    Chem Biol Interact; 1994 Apr; 91(1):51-63. PubMed ID: 8194125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beta-glucuronidase-inhibitory activity and hepatoprotective effect of Ganoderma lucidum.
    Kim DH; Shim SB; Kim NJ; Jang IS
    Biol Pharm Bull; 1999 Feb; 22(2):162-4. PubMed ID: 10077435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antioxidant properties of silybin glycosides.
    Kosina P; Kren V; Gebhardt R; Grambal F; Ulrichová J; Walterová D
    Phytother Res; 2002 Mar; 16 Suppl 1():S33-9. PubMed ID: 11933137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparative study on the stability of silybin and that in silymarin in buffers and biological fluids.
    Tang N; Wu D; Lu Y; Chen J; Zhang B; Wu W
    Drug Metab Lett; 2009 Apr; 3(2):115-9. PubMed ID: 19601873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo evaluation of silybin nanosuspensions targeting liver.
    Wang Y; Wang L; Liu Z; Zhang D; Zhang Q
    J Biomed Nanotechnol; 2012 Oct; 8(5):760-9. PubMed ID: 22888746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Formulation and biopharmaceutical evaluation of supersaturatable self-nanoemulsifying drug delivery systems containing silymarin.
    Tung NT; Tran CS; Nguyen HA; Nguyen TD; Chi SC; Pham DV; Bui QD; Ho XH
    Int J Pharm; 2019 Jan; 555():63-76. PubMed ID: 30448315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Silybin is metabolized by cytochrome P450 2C8 in vitro.
    Jancová P; Anzenbacherová E; Papousková B; Lemr K; Luzná P; Veinlichová A; Anzenbacher P; Simánek V
    Drug Metab Dispos; 2007 Nov; 35(11):2035-9. PubMed ID: 17670841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative effects of colchicine and silymarin on CCl4-chronic liver damage in rats.
    Favari L; Pérez-Alvarez V
    Arch Med Res; 1997; 28(1):11-7. PubMed ID: 9078581
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oxidised derivatives of silybin and their antiradical and antioxidant activity.
    Gazák R; Svobodová A; Psotová J; Sedmera P; Prikrylová V; Walterová D; Kren V
    Bioorg Med Chem; 2004 Nov; 12(21):5677-87. PubMed ID: 15465345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of hepatoprotective flavonolignans from silymarin.
    Polyak SJ; Morishima C; Lohmann V; Pal S; Lee DY; Liu Y; Graf TN; Oberlies NH
    Proc Natl Acad Sci U S A; 2010 Mar; 107(13):5995-9. PubMed ID: 20231449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel solid dispersion system for natural product-loaded medicine: silymarin-loaded solid dispersion with enhanced oral bioavailability and hepatoprotective activity.
    Hwang du H; Kim YI; Cho KH; Poudel BK; Choi JY; Kim DW; Shin YJ; Bae ON; Yousaf AM; Yong CS; Kim JO; Choi HG
    J Microencapsul; 2014; 31(7):619-26. PubMed ID: 24766208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of silymarin nanoemulsion against carbon tetrachloride-induced hepatic damage.
    Parveen R; Baboota S; Ali J; Ahuja A; Vasudev SS; Ahmad S
    Arch Pharm Res; 2011 May; 34(5):767-74. PubMed ID: 21656362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antioxidant and hepatoprotective effects of silymarin phytosomes compared to milk thistle extract in CCl4 induced hepatotoxicity in rats.
    El-Gazayerly ON; Makhlouf AI; Soelm AM; Mohmoud MA
    J Microencapsul; 2014; 31(1):23-30. PubMed ID: 23808477
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Studies of the metabolism and excretion of silybin in the rat].
    Bülles H; Bülles J; Krumbiegel G; Mennicke WH; Nitz D
    Arzneimittelforschung; 1975 Jun; 25(6):902-5. PubMed ID: 1174327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.